Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer By Ogkologos - January 14, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INSEMA study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer... April 19, 2021 Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping... March 15, 2022 Coping with COVID: New Stimulus Funds and Unemployment Benefit Update January 5, 2021 FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 Load more HOT NEWS Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in... Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients...
